In the initial challenge, the aim was to predict hits for the Tryptophan-Aspartate-Repeat domain 40 (WDR40) of the Leucine-Rich Repeat Kinase 2 (LRRK2), recognizing its pivotal role as a compelling target in the context of Parkinson’s disease (PD). Here, LRRK2 is linked to Parkinson disease.